The Efficacy and Safety of Carbon Ion Radiotherapy for Meningiomas: A Systematic Review and Meta-Analysis

Li, Jieyun; Li, Jingwen; Jin, Yuanchang; Li, Meixuan; Guo, Liping; Bing, Zhitong; Zhang, Qiuning; Bai, Fei; Wang, Xiaohu; Li, Xiuxia; Yang, Kun

doi:10.3389/fonc.2021.620534

Cited by 3 publications

(5 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the scoping review, many systematic reviews were found reporting the effectiveness and safety of proton therapy in several indications, such as meningioma of the brain and spinal cord [35,36], skull base chordoma [37], nasopharyngeal cancer [38], intracranial benign tumours [39], and gliomas [40]. However, presented systematic review is the first summary of available evidence about patients with HL or NHL.…”

Section: Discussionmentioning

confidence: 99%

Evidence for external beam radiotherapy in mediastinal Hodgkin and non-Hodgkin lymphoma – systematic review

Kowalska,

Sitarz-Kilian,

Jaros

et al. 2023

Ann Agric Environ Med.

View full text Add to dashboard Cite

Introduction and objective. Proton beam therapy (PBT) provides the opportunity for a more localized delivery of high energy protons and may reduce the damage to healthy tissues and vital organs. The aim of this review was to assess the effects of proton therapy for patients diagnosed with Hodgkin or non-Hodgkin lymphoma treated with mediastinal irradiation. Review methods. A systematic search of EMBASE, MEDLINE via OVID and Cochrane Library was conducted in May 2022 according to PRISMA guidelines to identify relevant data on the efficacy and toxicity of proton beam therapy for patients diagnosed with Hodgkin or non-Hodgkin lymphoma. Brief description of the state of knowledge. Of 566 screened abstracts (430 after de-duplication) 11 studies with a total of 529 patients were included. All studies were case series published between 2011-2021. Median range of follow-up time was 15-63.6 months. The overall survival (OS) for 2 years varied from 91% -98% for 5 of the included studies. Three of the included studies had favourable outcomes with 2-year progression-free survival (PFS) ranging from 73% -94%. Skin reaction, oesophagitis and fatigue were found to be the most common grade 1 and grade 2 toxicities. No acute or late grade 4 and higher toxicities/adverse events were observed. Summary. There are data indicating that PBT may to be an effective treatment against mediastinal Hodgkin and non-Hodgkin lymphoma. Because all the studies were case series, the authors of this review have little confidence in the evidence. There remains a need for well-designed randomized controlled trials to inform about the optimal approach to proton irradiation in HL and NHL.

show abstract

Section: Discussionmentioning

confidence: 99%

Evidence for external beam radiotherapy in mediastinal Hodgkin and non-Hodgkin lymphoma – systematic review

Kowalska,

Sitarz-Kilian,

Jaros

et al. 2023

Ann Agric Environ Med.

View full text Add to dashboard Cite

show abstract

“…Various recent (2020-2023) reviews and other publications consider clinical applications, experience, trials and outcomes for CIRT, some overviewing most or all sites with varying levels of detail 3,4,27,36,38,42,62,[100][101][102] and others discussing single applications only. [103][104][105][106][107][108][109] In 2022, Pompos et al 36 succinctly summarised the clinical indications as: radiation resistant malignancies, such as ACC, mucosal melanoma, NSCLC, liver cancer, bone and soft tissue sarcoma; recurrent previously irradiated cancers (especially rectal cancer), advanced gynaecological malignancies, oesophageal cancer, pancreatic cancer and hypoxic malignancies. For these, XRT and PBT are often not able to deliver sufficient target dose without undue probability of severe toxicity to organs-at-risk.…”

Section: Clinical Indications Patient Numbers and Application To Aust...mentioning

confidence: 99%

“…Various recent (2020–2023) reviews and other publications consider clinical applications, experience, trials and outcomes for CIRT, some overviewing most or all sites with varying levels of detail 3,4,27,36,38,42,62,100–102 and others discussing single applications only 103–109 . In 2022, Pompos et al 36 .…”

Section: Clinical Applications and Experience Of Cirtmentioning

confidence: 99%

The rationale for a carbon ion radiation therapy facility in Australia

Thwaites,

Prokopovich,

Garrett

et al. 2023

J of Medical Radiation Sci

View full text Add to dashboard Cite

Australia has taken a collaborative nationally networked approach to achieve particle therapy capability. This supports the under‐construction proton therapy facility in Adelaide, other potential proton centres and an under‐evaluation proposal for a hybrid carbon ion and proton centre in western Sydney. A wide‐ranging overview is presented of the rationale for carbon ion radiation therapy, applying observations to the case for an Australian facility and to the clinical and research potential from such a national centre.

show abstract

“…The diagnosis of meningioma is most common in middle and old age. The frequency increases with age, and women are twice as likely to be diagnosed as men ( 39 , 41 , 42 ).…”

Section: Meningiomasmentioning

confidence: 99%

“…PT is the most common PRT used in clinical practice ( 40 , 42 ). Another option is represented by CIRT, whose use is reserved especially for re-RT after disease progression ( 41 ).…”

Section: Meningiomasmentioning

confidence: 99%

The role of particle radiotherapy in the treatment of skull base tumors

et al. 2023

View full text Add to dashboard Cite

The skull base is an anatomically and functionally critical area surrounded by vital structures such as the brainstem, the spinal cord, blood vessels, and cranial nerves. Due to this complexity, management of skull base tumors requires a multidisciplinary approach involving a team of specialists such as neurosurgeons, otorhinolaryngologists, radiation oncologists, endocrinologists, and medical oncologists. In the case of pediatric patients, cancer management should be performed by a team of pediatric-trained specialists. Radiation therapy may be used alone or in combination with surgery to treat skull base tumors. There are two main types of radiation therapy: photon therapy and particle therapy. Particle radiotherapy uses charged particles (protons or carbon ions) that, due to their peculiar physical properties, permit precise targeting of the tumor with minimal healthy tissue exposure. These characteristics allow for minimizing the potential long-term effects of radiation exposure in terms of neurocognitive impairments, preserving quality of life, and reducing the risk of radio-induced cancer. For these reasons, in children, adolescents, and young adults, proton therapy should be an elective option when available. In radioresistant tumors such as chordomas and sarcomas and previously irradiated recurrent tumors, particle therapy permits the delivery of high biologically effective doses with low, or however acceptable, toxicity. Carbon ion therapy has peculiar and favorable radiobiological characteristics to overcome radioresistance features. In low-grade tumors, proton therapy should be considered in challenging cases due to tumor volume and involvement of critical neural structures. However, particle radiotherapy is still relatively new, and more research is needed to fully understand its effects. Additionally, the availability of particle therapy is limited as it requires specialized equipment and expertise. The purpose of this manuscript is to review the available literature regarding the role of particle radiotherapy in the treatment of skull base tumors.

show abstract

The Efficacy and Safety of Carbon Ion Radiotherapy for Meningiomas: A Systematic Review and Meta-Analysis

Cited by 3 publications

References 65 publications

Evidence for external beam radiotherapy in mediastinal Hodgkin and non-Hodgkin lymphoma – systematic review

Evidence for external beam radiotherapy in mediastinal Hodgkin and non-Hodgkin lymphoma – systematic review

The rationale for a carbon ion radiation therapy facility in Australia

The role of particle radiotherapy in the treatment of skull base tumors

Contact Info

Product

Resources

About